KalVista Pharmaceuticals Inc’s recently made public that its CHIEF EXECUTIVE OFFICER Palleiko Benjamin L unloaded Company’s shares for reported $0.52 million on Jul 09 ’25. In the deal valued at $15.69 per share,32,979 shares were sold. As a result of this transaction, Palleiko Benjamin L now holds 369,595 shares worth roughly $5.63 million.
Then, Yea Christopher sold 30,250 shares, generating $474,698 in total proceeds. Upon selling the shares at $15.69, the CHIEF DEVELOPMENT OFFICER now owns 127,939 shares.
Before that, Palleiko Benjamin L sold 7,169 shares. KalVista Pharmaceuticals Inc shares valued at $103,950 were divested by the CHIEF EXECUTIVE OFFICER at a price of $14.50 per share. As a result of the transaction, Palleiko Benjamin L now holds 315,074 shares, worth roughly $4.8 million.
JMP Securities initiated its KalVista Pharmaceuticals Inc [KALV] rating to a Mkt outperform in a research note published on January 31, 2025; the price target was $19. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in early January with a ‘”a Buy”‘ rating. BofA Securities began covering KALV with “Buy” recommendation on December 18, 2024. H.C. Wainwright started covering the stock on June 15, 2020. It rated KALV as “a Buy”.
Price Performance Review of KALV
On Monday, KalVista Pharmaceuticals Inc [NASDAQ:KALV] saw its stock jump 4.82% to $15.22. Over the last five days, the stock has gained 1.06%. KalVista Pharmaceuticals Inc shares have risen nearly 21.08% since the year began. Nevertheless, the stocks have risen 79.69% over the past one year. While a 52-week high of $16.32 was reached on 07/10/25, a 52-week low of $7.30 was recorded on 01/13/25.
Levels Of Support And Resistance For KALV Stock
The 24-hour chart illustrates a support level at 14.30, which if violated will result in even more drops to 13.38. On the upside, there is a resistance level at 15.69. A further resistance level may holdings at 16.16.
How much short interest is there in KalVista Pharmaceuticals Inc?
A steep rise in short interest was recorded in KalVista Pharmaceuticals Inc stocks on 2025-06-13, growing by 0.14 million shares to a total of 6.25 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.11 million shares. There was a rise of 2.27%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 29, 2019 when SVB Leerink began covering the stock and recommended ‘”an Outperform”‘ rating along with a $31 price target.
